enfuvirtide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
peptides and glycopeptides 1010 159519-65-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • enfuvirtide
  • fuzeon
  • pentafuside
Enfuvirtide interferes with the entry of HIV-1 into cells by inhibiting fusion of viral and cellular membranes. Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes.
  • Molecular weight: 4491.95
  • Formula: C204H301N51O64
  • CLOGP:
  • LIPINSKI: None
  • HAC: 115
  • HDO: 63
  • TPSA: 1902.89
  • ALOGS:
  • ROTB: 151

Drug dosage:

DoseUnitRoute
0.18 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1000 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.57 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.07 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.36 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.08 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
March 13, 2003 FDA ROCHE
May 27, 2023 EMA ROCHE REGISTRATION GMBH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Schizophrenia 916.28 265.43 192 3547 14722 90609986
Hypomania 773.53 265.43 153 3586 8744 90615964
Jaundice cholestatic 731.28 265.43 149 3590 9894 90614814
Cholelithiasis 676.10 265.43 192 3547 52314 90572394
Psychotic disorder 563.07 265.43 149 3590 31081 90593627
Blood bilirubin increased 514.29 265.43 149 3590 43321 90581387
Hepatotoxicity 506.46 265.43 149 3590 45693 90579015
Asthma-chronic obstructive pulmonary disease overlap syndrome 417.60 265.43 83 3656 4816 90619892
Total lung capacity increased 415.56 265.43 83 3656 4938 90619770
Sarcoidosis 353.20 265.43 83 3656 10590 90614118
Nasal polyps 351.62 265.43 83 3656 10797 90613911
Rhinitis allergic 315.87 265.43 83 3656 16702 90608006
Cardiac murmur 309.24 265.43 83 3656 18111 90606597
Bronchiectasis 292.40 265.43 83 3656 22247 90602461

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Depression 1273.44 173.48 445 3435 110918 42506537
Drug interaction 930.32 173.48 456 3424 266543 42350912
Psychiatric decompensation 682.70 173.48 139 3741 4083 42613372
Mitochondrial toxicity 653.92 173.48 124 3756 2491 42614964
Depression suicidal 645.46 173.48 127 3753 3118 42614337
Tearfulness 635.88 173.48 127 3753 3373 42614082
Lipodystrophy acquired 613.63 173.48 123 3757 3327 42614128
Depressive symptom 570.72 173.48 118 3762 3735 42613720
Psychomotor skills impaired 535.37 173.48 118 3762 5086 42612369
Eyelid ptosis 532.99 173.48 123 3757 6538 42610917
Loss of personal independence in daily activities 494.90 173.48 181 3699 49635 42567820
Paranoia 455.88 173.48 126 3754 13900 42603555
Diplopia 392.80 173.48 122 3758 20194 42597261
Psychotic disorder 380.42 173.48 130 3750 29078 42588377
Progressive external ophthalmoplegia 359.20 173.48 68 3812 1343 42616112
Suicidal ideation 306.85 173.48 127 3753 48034 42569421
Anxiety 234.36 173.48 141 3739 118419 42499036

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psychotic disorder 958.88 202.67 278 6998 50659 110531364
Depression 928.16 202.67 438 6838 316897 110265126
Schizophrenia 771.65 202.67 196 7080 21630 110560393
Drug interaction 761.46 202.67 446 6830 499737 110082286
Hypomania 690.72 202.67 155 7121 10055 110571968
Psychiatric decompensation 677.43 202.67 138 7138 5627 110576396
Mitochondrial toxicity 660.08 202.67 123 7153 3122 110578901
Lipodystrophy acquired 649.60 202.67 128 7148 4396 110577627
Depression suicidal 629.38 202.67 126 7150 4698 110577325
Jaundice cholestatic 615.12 202.67 151 7125 14457 110567566
Tearfulness 575.72 202.67 126 7150 7269 110574754
Cholelithiasis 565.24 202.67 196 7080 63226 110518797
Psychomotor skills impaired 531.33 202.67 117 7159 6941 110575082
Depressive symptom 510.85 202.67 117 7159 8297 110573726
Eyelid ptosis 482.02 202.67 122 7154 13205 110568818
Paranoia 432.73 202.67 125 7151 22249 110559774
Hepatotoxicity 396.61 202.67 151 7125 63249 110518774
Total lung capacity increased 386.08 202.67 85 7191 5027 110576996
Progressive external ophthalmoplegia 380.54 202.67 68 7208 1352 110580671
Blood bilirubin increased 370.11 202.67 151 7125 75821 110506202
Asthma-chronic obstructive pulmonary disease overlap syndrome 367.80 202.67 85 7191 6259 110575764
Diplopia 340.33 202.67 121 7155 41773 110540250
Loss of personal independence in daily activities 337.04 202.67 174 7102 149846 110432177
Sarcoidosis 310.03 202.67 85 7191 12494 110569529
Nasal polyps 305.97 202.67 85 7191 13115 110568908
Rhinitis allergic 280.28 202.67 85 7191 17837 110564186
Suicidal ideation 261.05 202.67 126 7150 93811 110488212
Cardiac murmur 257.68 202.67 86 7190 24542 110557481
Bronchiectasis 221.05 202.67 85 7191 36408 110545615

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AX07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Other antivirals
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D019380 Anti-HIV Agents
MeSH PA D023581 HIV Fusion Inhibitors
FDA MoA N0000175615 Fusion Protein Inhibitors
FDA EPC N0000175616 Human Immunodeficiency Virus 1 Fusion Inhibitor
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:59886 HIV fusion inhibitor
CHEBI has role CHEBI:64946 anti-HIV agent

Related Drugs by ATC class:

J05AX Other antivirals 15 drugs
amenamevirbaloxavir marboxilbulevirtidefavipiravirfostemsaviribalizumabinosine pranobexlenacapavirletermovirmaravirocmaribavirmoroxydine show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Pneumonia contraindication 233604007 DOID:552
Breastfeeding (mother) contraindication 413712001
Smokes tobacco daily contraindication 449868002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.09 acidic
pKa2 3.55 acidic
pKa3 3.77 acidic
pKa4 3.97 acidic
pKa5 4.16 acidic
pKa6 4.38 acidic
pKa7 4.66 acidic
pKa8 9.65 acidic
pKa9 11.84 acidic
pKa10 12.17 acidic
pKa11 12.25 acidic
pKa12 12.34 acidic
pKa13 12.44 acidic
pKa14 12.6 acidic
pKa15 12.67 acidic
pKa16 12.74 acidic
pKa17 12.82 acidic
pKa18 12.92 acidic
pKa19 12.93 acidic
pKa20 13.14 acidic
pKa21 13.18 acidic
pKa22 13.22 acidic
pKa23 13.23 acidic
pKa24 13.3 acidic
pKa25 13.43 acidic
pKa26 13.44 acidic
pKa27 13.49 acidic
pKa28 13.53 acidic
pKa29 13.57 acidic
pKa30 13.59 acidic
pKa31 13.65 acidic
pKa32 13.78 acidic
pKa33 13.78 acidic
pKa34 13.8 acidic
pKa35 13.88 acidic
pKa36 13.93 acidic
pKa37 11.11 Basic
pKa38 10.51 Basic
pKa39 6.69 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Transmembrane glycoprotein gp41 Membrane other INHIBITOR CHEMBL CHEMBL
Envelope glycoprotein Viral envelope protein WOMBAT-PK
GP41 Viral envelope protein EC50 8 CHEMBL

External reference:

IDSource
4021375 VUID
N0000171600 NUI
D02499 KEGG_DRUG
4021375 VANDF
C0537439 UMLSCUI
CHEBI:608828 CHEBI
CHEMBL525076 ChEMBL_ID
D000077560 MESH_DESCRIPTOR_UI
DB00109 DRUGBANK_ID
8063 INN_ID
19OWO1T3ZE UNII
16130199 PUBCHEM_CID
139896 RXNORM
17175 MMSL
46376 MMSL
d04853 MMSL
009919 NDDF
398902008 SNOMEDCT_US
409127007 SNOMEDCT_US

Pharmaceutical products:

None